MedTrace Logo

Bioavailability Study of Propranolol Under Fasting Conditions

NCT00653120 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2008-04-04

No results posted yet for this study

Summary

To compare the single-dose bioavailability of Propranolol 160 Mg ER capsules with Inderal-La

Conditions

  • To Determine Bioequivalence Under Fasting Conditions

Interventions

DRUG

Propranolol

ER capsules, 160 mg, single-dose

DRUG

Inderal-LA

ER capsules, 160 mg, single-dose

Sponsors & Collaborators

  • SFBC Anapharm

    collaborator INDUSTRY

  • Par Pharmaceutical, Inc.

    lead INDUSTRY

Principal Investigators

  • Denis Audet · SFBC Anapharm

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2005-11-30
Completion
2005-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00653120 on ClinicalTrials.gov